

## Review

## PUVA (psoralen + UVA) photochemotherapy: processes triggered in the cells

Z. Zarebska <sup>a,\*</sup>, E. Waszkowska <sup>a</sup>, S. Caffieri <sup>b</sup>, F. Dall'Acqua <sup>b</sup><sup>a</sup> *Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Ul. Pawinskiego 5, PL-02106 Warszawa, Poland*<sup>b</sup> *Department of Pharmaceutical Sciences, University of Padova, and Center for Chemical Investigations of Drugs (associated to the National Institute for the Chemistry of Biological Systems), National Research Council, Padua, Italy*

Received 9 May 2000; accepted 20 August 2000

Dedicated to Professor Pietro Pratesi

---

**Abstract**

Photochemotherapy using psoralens and UVA is a treatment used widely in some skin diseases, in cutaneous lymphomas and in autoimmune diseases. This review has selected recent publications dealing with the photochemical processes triggered in the cells by UVA radiation and psoralen treatment. The photochemical changes initiated in the cell membranes were described. © 2000 Published by Elsevier Science S.A. All rights reserved.

**Keywords:** Psoralen photoaddition; Phospholipids; Apoptosis; PUVA-photochemotherapy

---

**1. Introduction**

In PUVA therapy [1], which includes the joint action of psoralens as drug and of UVA as sensitising radiation, various cellular targets are hit, among which blood peripheral circulating lymphocytes play a particular role [2]. The therapy, by initiating some reactions in lymphocytes, leads to alleviation of many human diseases which are associated with immune imbalance [3]. The role of lymphocytes in restoring the immune balance was brought up by a successful treatment of cutaneous T-cell lymphoma by the photopheresis: extracorporeal irradiation of only 1/8 of the whole peripheral lymphocytes has improved the state of patients significantly [2]. Although numerous studies were devoted to the mechanism of PUVA treatment, no straightforward correlation was found between photochemical damage and immune response reflected in apoptosis [4,5] and in the spectrum of cytokine release

from the cells [6,7]. This is in contrast with the cell cytotoxicity exerted through nuclear DNA damage [8] or pigmentation induced by DNA repair in melanocytes [9,10], phenomena rather well understood and connected directly to DNA photoproducts. In this review an attempt was made to collect the data on photochemical reactions in the cell membranes in the context with observed physiological responses of the whole cell.

In the early microscopic studies carried out on guinea pig treated topically with PUVA it was noted that psoralen shows preferential binding to the keratine layer, cell membranes and intercellular matrix [11]. After UVA irradiation, the photoadducts were localized in the same sites, and the photoadducts in nuclear DNA were revealed only after special pretreatments with ethanol, alkali or proteolytic enzymes. Although those studies were fairly qualitative, they have indicated that psoralen photoproducts formation in the membrane input a significant damage to the cell different from that induced in the cell nuclei. It was suggested that phospholipids of the cell membranes [12,13] and their proteins [14–17] in addition to nuclear DNA [8,17] can be a target of action of PUVA therapy.

---

\* Corresponding author. Fax: +48-39-121 623.

E-mail address: zozar@ibbrain.ibb.waw.pl (Z. Zarebska).



The characterization of lecithin photoproducts shown in Scheme 1 was based on mass spectroscopy and NMR analysis [31,32,35]. Mass spectra of cyclobutane photoadducts had to be determined by soft ionizing technique since under electron impact technique the cyclobutane ring underwent splitting [32]. The best way was to separate irradiated mixture by HPLC connected with simultaneous ion spray mass spectrometric detector [31]. Alternatively, the NMR techniques are at hand to trace the photoadduct formation by means of two-dimensional NMR analysis carried out on lecithin–psoralen irradiated mixture, without any purification step [35]. In fact, the set of four cross-peaks indicating cyclobutane ring protons resonate in a region of the spectrum (between 3 and 2 ppm) in which they are not hidden by other signals of either psoralen or lecithin, thus allowing their easy detection. Moreover, these protons have slightly different chemical shifts depending on the stereochemistry of isomers (table 1 of Ref. [35]).


Characterization of photoadducts in the mixture is complicated by the accompanying oxidation reactions of both lecithin and psoralen molecules. For instance, the photoaddition of a water molecule to psoralen can also occur in oxygenated solutions [36,37]. The adducts are unstable in the various eluents used with TLC separation, and it was noted that the cyclobutane adducts of non esterified fatty acids appeared to be less stable in comparison to their more stable methyl esters or lecithin adducts [32,34]. The latter feature seems to explain the difficulty of their detection *in vivo*.

In contrast to the great effort devoted to study the photochemical reactions of psoralens with lipids *in*

*vitro*, scarce evidence is available on their detection *in vivo* or in cell cultures: photoadducts of trimethylangelicin to oleic and linoleic acids were found in rat skin [30], the 8-methoxypsoralen cyclobutane adduct to linoleic acid was detected in lymphocytes [38], and oxidized unsaturated fatty acids were detected in keratinocyte cell culture [26].

## 5. Cyclobutane adducts of psoralen in melanogenesis

The cyclobutane adducts *in vivo* might be stable enough to initiate the cascade of signal transduction. It was shown that enhancement of protein kinase C (PKC) activity in human platelets occurs upon addition of freshly HPLC-isolated psoralen cyclobutane adducts of oleic, linoleic and linolenic acids [39]. The enhancement of kinase activity induced by external addition of cyclobutane adducts seems to be important in melanogenesis as it was found with cultured human melanocytes [40,41]. It was suggested that the cyclobutane adducts of psoralen to unsaturated fatty acids can mimic the action of 1,2-diacylglycerol (DAG) [40], a known agent which stimulates human melanogenesis [42]. In contrast to the fatty acid adducts, analogous lecithin adducts seem to be inactive in platelets, their action probably requiring enzymatic release of photoadducts by phospholipase A<sub>2</sub> (PLA<sub>2</sub>). The resulting residue of enzymatic lysis by PLA<sub>2</sub>, lysophosphatidylcholine, was shown to enhance synergistically the DAG dependent activation of PKC [43]. Scheme 2 presents the proposed scheme of melanogenesis activation by lecithin photoadducts.



Scheme 2. Melanogenesis activation by PUVA treatment [40]. Circled numbers 1–5 indicate consecutive stages of reaction. Protein-P, phosphorylated protein.

According to Scheme 2, UVA-excited 8-MOP undergoes cyclobutane-type attachment to phospholipids, from which the photoadduct of fatty acid is released by PLA<sub>2</sub>. The 8-MOP-fatty acid adduct, transferred from membrane to the cytosol, activates protein kinase C, playing the role of second messenger. The activation of PKC was monitored by measuring the extent of phosphorylation of P47 protein in human platelets, and PKC stimulation has been observed in concentrations similar to DAG [31,39]. These reactions lead then to melanogenesis through unknown pathways.

## 6. PUVA and immune response

Recently, an increasing number of research works has indicated that photochemically damaged cells participate in regulating the immune response upon treatment with PUVA or UV alone [19]. The enhanced synthesis of MHC I receptors [44] or induction of MHC-I-associated peptides [45,46], overexpression of IL-15 cytokine [47] or transcription factor NF- $\kappa$ B [48] following photochemical treatment could be examples of that line of research. Also photooxidation of lipids [12–14,29] and of psoralens themselves [49] may lead to better understanding an overall picture of transformations induced by UVA/PUVA treatment. The protein photochemistry is lagging behind; the promising study of a psoralen–tyrosine photoconjugate [50] will hopefully initiate a new line of research.

The particular information on PUVA-induced immune response derives from studies on photopheresis [23]. In this treatment, peripheral blood leukocytes are separated and exposed for 1.5 h to 8-MOP and UVA irradiation, followed by reinfusion back to the patient. The withdrawn patient's blood (125 ml per cycle) is centrifuged in extracorporeal photopheresis (ECP) machine, and the buffy coats of six cycles are collected sequentially in the treatment bag. The centrifuged plasma and erythrocytes are directly reinfused into the patient, before starting a new cycle. The stabilized aqueous solution of 8-MOP is added to the treatment bag at the final concentration of 100–150 ng/ml [23]. Alternatively, the patients are given orally the appropriate amount of 8-MOP in capsules [24]. The treatment bag is connected to a disposable system where the leukocytes are exposed to UVA irradiation (2 J/cm<sup>2</sup>). The ECP treatment is given every 4 weeks on 2 consecutive days.

It was observed that reinfused lymphocytes are still viable, however gradually undergoing apoptosis within several days [23,22]. It was hypothesized that during the highly regulated process of apoptosis the irradiated lymphocytes have altered membrane receptors and release cytokines which modulate the whole immune system [6,23].

## 7. Apoptosis

Apoptosis is considered to be the main mechanism of action of ultraviolet light therapy and PUVA chemotherapy which induces reduction of number of activated lymphocytes infiltrating the skin [51]. Apoptosis studies enabled to differentiate a fraction of T-cell of the circulating lymphocytes [21–24], and of T-helper cells infiltrating the skin abundantly in some diseases [18].

It was directly evidenced that narrow band UVB (312 nm) induces apoptosis of T cells residing within psoriatic lesions [52]. Treatment by psoralen + UVA suppress proinflammatory cytokine release from monocytes [6] and induces apoptosis of lymphocytes [22] and apoptosis of epidermal cells in culture [21,53].

Godar has postulated that there are two main routes of apoptosis induction in the lymphocytes: one 'preprogrammed' which can be detected within 20 min up to 4 h after the irradiation, and the other, starting 12–24 h afterwards [54]. It can be hypothesized that early induced apoptosis does not require sensitizing drug but is triggered by UVA radiation alone which affects cell receptors and appropriate transcription factors [48]. The delayed stage of induced apoptosis could be triggered by photoproducts derived from DNA and from plasma membranes. It was noted that UVA-induced delayed apoptosis is accompanied by the decline of expression of protein kinase C, and of all its six isoenzymes [55].

Recently, it was discovered that apoptosis is connected with overproduction of Bcl-2 and Bax proteins regulating caspase chain reactions [56,57]. Endothelial rat aortic cells irradiated with pharmacological doses of 6 J/cm<sup>2</sup> of UVA were inducing overexpression of Bcl-2 mRNA, persisting 48 h. Alternatively, Bax overexpression was detected in the cells not activated by the proinflammatory cytokines and in the presence of nitric oxide synthase inhibitors [57]. The concept of nitric oxide and Bcl-2 protein acting as antioxidants [56] looks promising since it furnishes the experimental insight into the cell defense mechanism against UVA radiation. The apoptosis of lymphocytes infiltrating the skin induced by UVA/PUVA treatment was suggested to be a way of recovering balance in some skin disorders [51,52,58,59].

## 8. Conclusions

Characterization of photoproducts of the membrane phospholipids made a progress in understanding of the mechanism of PUVA treatment. Kinase phosphorylation induced by those photoproducts, cytokine synthesis and overexpression of proteins regulating apoptosis were the physiological reactions triggered by PUVA

within the cell studied mostly. Apoptosis studies made possible to quantify the number of lymphocytes affected by the UVA/PUVA treatment, localized in both sites: residing in the skin and circulating in the peripheral blood.

## References

- [1] M.A. Pathak, T.B. Fitzpatrick, The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD, *J. Photochem. Photobiol. B: Biol.* 14 (1992) 3–22.
- [2] F.P. Gasparro, *Extracorporeal Phototherapy: Clinical Aspects and the Molecular Basis for Efficacy*, Landes, Austin, TX, 1994, p. 139.
- [3] W.L. Morison, B. Honig, D. Karp, Photochemotherapy for miscellaneous diseases, in: H. Hönigsmann, G. Jori, A.R. Young (Eds.), *The Fundamental Bases of Phototherapy*, OEMF, Milano, 1996, pp. 53–65.
- [4] D.E. Godar, A.D. Lucas, Spectral dependence of UV-induced immediate and delayed apoptosis: the role of membrane and DNA damage, *Photochem. Photobiol.* 62 (1995) 108–113.
- [5] D.E. Godar, Preprogrammed and programmed cell death mechanism of apoptosis: UV-induced immediate and delayed apoptosis, *Photochem. Photobiol.* 63 (1996) 625–630.
- [6] P. Neuner, B. Charvat, R. Knobler, R. Kirnbauer, A. Schwarz, T.A. Luger, T. Schwarz, Cytokine release by peripheral blood mononuclear cells is affected by 8-methoxypsoralen plus UVA, *Photochem. Photobiol.* 59 (1994) 182–188.
- [7] T. Schwarz, UV light affects cell membrane and cytoplasmic targets, *J. Photochem. Photobiol. B: Biol.* 44 (1998) 91–96.
- [8] D. Averbeck, M. Dardalhon, N. Magana-Schwencke, L. Borges, M.V. Meniel, S. Boiteux, E. Sage, New aspects of the repair and genotoxicity of psoralen photoinduced lesions in DNA, *J. Photochem. Photobiol. B: Biol.* 14 (1992) 47–63.
- [9] B.A. Gilchrist, H.-Y. Park, M.S. Eller, M. Yaar, Mechanism of ultraviolet light-induced pigmentation, *Photochem. Photobiol.* 63 (1996) 1–10.
- [10] M.S. Eller, T. Maeda, C. Magnoni, D. Atwal, B.A. Gilchrist, Enhancement of DNA repair in human skin cells by thymidine dinucleotides: evidence for a p53-mediated mammalian SOS response, *Proc. Natl. Acad. Sci. USA* 94 (1997) 12627–12632.
- [11] M.A. Pathak, Z. Zarebska, M.C. Mihm, M. Jarzabek-Chorzelska, T.C. Chorzelski, S. Jablonska, Detection of DNA-psoralen photoadducts in mammalian skin, *J. Invest. Dermatol.* 86 (1986) 308–315.
- [12] D.I. Roschupkin, A.B. Pelenitsyn, A.Ya. Potapenko, V.V. Talitsky, Yu.A. Vladimirov, Study of the effects of ultraviolet light on biomembranes — IV The effect of oxygen on UV-induced hemolysis and lipid photoperoxidation in rat erythrocytes and liposomes, *Photochem. Photobiol.* 21 (1975) 63–69.
- [13] Z. Zarebska, Cell membrane, a target for PUVA therapy, *J. Photochem. Photobiol. B: Biol.* 23 (1994) 101–109.
- [14] I.E. Kochevar, UV-induced protein alterations and lipid oxidation in erythrocyte membranes, *Photochem. Photobiol.* 52 (1990) 795–800.
- [15] I.M. Schmitt, S. Chimenti, F.P. Gasparro, Psoralen–protein photochemistry — a forgotten field, *J. Photochem. Photobiol. B: Biol.* 27 (1995) 101–107.
- [16] F. Bordin, F. Carlasse, L. Busolini, F. Baccichetti, Furocoumarin sensitization induces DNA protein cross-links, *Photochem. Photobiol.* 58 (1993) 133–136.
- [17] G.M.J. Beijersbergen van Henegouwen, E.T. Wijn, S.A. Schoonderwoerd, A method for the determination of PUVA-induced in vivo irreversible binding of 8-methoxypsoralen to epidermal lipids, proteins and DNA/RNA, *J. Photochem. Photobiol. B: Biol.* 3 (1989) 631–635.
- [18] A. Morita, T. Werfel, H. Stege, C. Ahrens, K. Karmann, M. Grewe, S. Grether-Beck, T. Ruzicka, A. Kapp, L.-O. Klotz, H. Sies, J. Krutmann, Evidence that singlet-oxygen-induced human T-helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy, *J. Exp. Med.* 186 (1997) 1763–1768.
- [19] J. Krutmann, Therapeutic photoimmunology: photoimmunological mechanisms in photo(chemo)therapy, *J. Photochem. Photobiol. B: Biol.* 44 (1998) 159–164.
- [20] J.Z. Beer, K.M. Olvey, S.A. Miller, D.P. Thomas, D.E. Godar, Non nuclear damage and cell lysis are induced by UVA, but not UVB or UVC radiation in three strains of L5178Y cells, *Photochem. Photobiol.* 58 (1993) 676–681.
- [21] A. Schindl, G. Klosner, H. Hönigsmann, G. Jori, P.G. Calzavara-Pinton, F. Trautinger, Flow cytometric quantification of UV-induced death in human squamous cell carcinoma-derived cell line: dose and kinetics studies, *J. Photochem. Photobiol. B: Biol.* 44 (1998) 97–106.
- [22] E.K. Yoo, A.H. Rook, R. Elenitas, F.P. Gasparro, B.R. Vowels, Apoptosis induction by ultraviolet A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action, *J. Invest. Dermatol.* 107 (1996) 235–242.
- [23] D.N.H. Enomoto, P.A. Schellekens, S.-L. Yong, I.J.M. ten Berge, J.R. Mekkes, J.D. Bos, Extracorporeal photochemotherapy (photopheresis) induces apoptosis in lymphocytes: a possible mechanism of action of PUVA therapy, *Photochem. Photobiol.* 65 (1997) 177–180.
- [24] S.E. Shephard, F.O. Nestle, R. Panizzon, Pharmacokinetics of 8-methoxypsoralen during extracorporeal photopheresis, *Photodermatol. Photoimmunol. Photomed.* 15 (1999) 64–74.
- [25] T. Sá e Melo, C. Sousa, Solvent-dependent excited state properties of psoralens. A model to their antiproliferative action, in: E. Kohen, J.G. Hirschberg (Eds.), *Analytical Use of Fluorescent Probes in Oncology*, NATO ASI Series A: Life Sciences, vol. 286, Plenum Press, New York, 1996, pp. 405–409.
- [26] C. Sousa, T. Sá e Melo, J.-C. Mazière, R. Santus, PUVA induced mortality in NCTC 2544 keratinocytes: is it related to the microenvironmental properties of the excited states of psoralens?, *Photochem. Photobiol.* 67 (1998) 561–564.
- [27] C. Sousa, T. Sá e Melo, Microenvironment effects on the excited state properties of psoralens: a clue to their photobiological activity, *Photochem. Photobiol.* 63 (1996) 182–186.
- [28] T. Reinheckel, M. Böhne, W. Halangk, W. Augustin, H. Gollnick, Evaluation of UVA-mediated oxidative damage to proteins and lipids in extracorporeal photoimmunology, *Photochem. Photobiol.* 69 (1999) 566–570.
- [29] W. Korytowski, P.G. Geiger, W.A. Girotti, Enzymatic reducibility in relation to cytotoxicity for various cholesterol hydroperoxides, *Biochemistry* 35 (1996) 8670–8679.
- [30] S. Caffieri, S.A. Scoonderwoerd, A. Daga, F. Dall'Acqua, G.M.J. Beijersbergen van Henegouwen, Photoaddition of 4,6,4'-trimethylangelicin to unsaturated fatty acids: possible 'in vivo' occurrence, *Med. Biol. Environ.* 17 (1989) 796–804.
- [31] S. Frank, S. Caffieri, A. Raffaelli, D. Vedaldi, F. Dall'Acqua, Characterization of psoralen-oleic acid cycloadducts and their possible involvement in membrane photodamage, *J. Photochem. Photobiol. B: Biol.* 44 (1998) 39–44.
- [32] Z. Zarebska, E. Waszkowska, S. Caffieri, F. Dall'Acqua, Photoreactions of psoralens with lecithins, *J. Photochem. Photobiol. B: Biol.* 45 (1998) 122–130.
- [33] K.G. Specht, R.W. Midden, M.R. Chedekel, Photocycloaddition of 4,5',8-trimethyl-psoralen and oleic acid methyl ester: product structures and reaction mechanism, *J. Org. Chem.* 54 (1989) 4125–4134.
- [34] E. Waszkowska, Ph.D. Thesis, IBB PAN, Warsaw, 1999.

- [35] E. Waszkowska, Z. Zarebska, J. Poznanski, I. Zhukov, Spectroscopic detection of photoproducts in lecithin model system after 8-methoxypsoralen plus UV-A treatment, *J. Photochem. Photobiol. B: Biol.* 55 (2000) 145–154.
- [36] A. Moysan, A. Cazaussus, F. Gaboriau, J.C. Blais, N. Sellier, P. Vigny, Structure of 3-carbethoxypsoralen photolysis product, *Photochem. Photobiol.* 47 (1988) 327–335.
- [37] K.A. Marley, R.A. Larson, A new photoproduct from furocoumarin photolysis in dilute aqueous solution: 5-formyl-6-hydroxybenzofuran, *Photochem. Photobiol.* 59 (1994) 503–505.
- [38] S. Caffieri, Z. Zarebska, F. Dall'Acqua, Membrane lymphocyte damage by 8-methoxypsoralen and UVA-radiation, *Med. Biol. Environ.* 19 (1991) 45–50.
- [39] S. Caffieri, M. Ruzzene, B. Guerra, S. Frank, D. Vedaldi, F. Dall'Acqua, Psoralen-fatty acid cycloadducts activate protein kinase C (PKC) in human platelets, *J. Photochem. Photobiol. B: Biol.* 22 (1994) 253–256.
- [40] F.A. Anthony, H.M. Laboda, M.E. Costlow, Psoralen-fatty acid adducts activate melanocyte protein kinase C: a proposed mechanism for melanogenesis induced by 8-methoxypsoralen and ultraviolet A light, *Photodermatol. Photoimmunol. Photomed.* 13 (1997) 9–16.
- [41] S. Frank, D. Vedaldi, S. Caffieri, A. Schothorst, F. Dall'Acqua, PUVA therapy of vitiligo: psoralen-unsaturated fatty acids cycloadducts stimulate melanogenesis in human melanocytes, *Melanoma Res.* 4 (suppl. 2) (1994) 34–35.
- [42] P.R. Gordon, B.A. Gilchrest, Human melanogenesis is stimulated by diacylglycerol, *J. Invest. Dermatol.* 93 (1989) 700–702.
- [43] Y. Asaoka, M. Oka, K. Yoshida, Y. Nishizuka, Lysophosphatidylcholine as a possible second messenger synergistic to diacylglycerol and calcium ion for T-lymphocyte activation, *Biochem. Biophys. Res. Commun.* 178 (1991) 1378–1385.
- [44] A.C.E. Moor, I.M. Schmitt, G.M.J. Beijersbergen van Henegouwen, S. Chimenti, R.L. Edelson, F.P. Gasparro, Treatment with 8-MOP and UVA enhances MHC class I synthesis in RMA cells: preliminary results, *J. Photochem. Photobiol. B: Biol.* 29 (1995) 193–198.
- [45] S. Imaeda, A. Felli, I.M. Schmitt, S. Chimenti, R.L. Edelson, Induction of functional empty class I major histocompatibility complex glycoproteins by photoactivated 8-methoxypsoralen, *J. Invest. Dermatol.* 107 (1996) 887–890.
- [46] I.M. Schmitt, C. Mordenti, V. Flati, S. Martinotti, S. Chimenti, in: IFN- $\alpha$  mediated gene activation after PUVA treatment, 3d International Workshop on Dermatology, Desenzano del Garda, Italy, April 1998, Abstracts, p. 18.
- [47] M. Mohamadzaheh, A. Takashima, I. Dougherty, J. Knop, P.R. Bergstresser, P.D. Cruz, Jr., Ultraviolet B radiation up-regulates the expression of IL-15 in human skin, *J. Immunol.* 155 (1995) 4492–4496.
- [48] S. Legrand-Poels, S. Schoonbrodt, J.Y. Matroule, J. Piette, NF- $\kappa$ B: an important transcription factor in photobiology, *J. Photochem. Photobiol. B: Biol.* 45 (1998) 1–8.
- [49] A.A. Kyagova, N.N. Zhuravel, M.V. Malakhov, E.P. Lysenko, W. Adam, C.R. Saha-Moller, A.Ya. Potapenko, Suppression of delayed-type hypersensitivity and hemolysis induced by previously photooxidized psoralen: effect of fluence rate and concentration, *Photochem. Photobiol.* 65 (1997) 694–700.
- [50] S.S. Sastry, Isolation and partial characterization of a novel psoralen-tyrosine photoconjugate from a photoreaction with a natural protein, *Photochem. Photobiol.* 65 (1997) 937–944.
- [51] D.A. Norris, J.B. Travers, D.Y.M. Leung, Lymphocyte activation in the pathogenesis of psoriasis, *J. Invest. Dermatol.* 109 (1997) 1–4.
- [52] M. Ozawa, K. Ferenczi, T. Kikuchi, I. Cardinale, L.M. Austin, T.R. Coven, L.H. Burak, J.G. Krueger, 312-nanometer ultraviolet B light (narrow band UVB) induces apoptosis of T cells within psoriatic lesions, *J. Exp. Med.* 189 (1999) 711–718.
- [53] R. Gniadecki, M. Hansen, H.C. Wulf, Two pathways for induction of apoptosis by ultraviolet radiation in cultured human keratinocytes, *J. Invest. Dermatol.* 109 (1997) 722–727.
- [54] D.E. Godar, UVA1 radiation triggers two different final apoptotic pathways, *J. Invest. Dermatol.* 112 (1998) 3–12.
- [55] D. Leszczynski, S. Fragerholm, K. Leszczynski, The effect of broad band UVA radiation on myeloid leukemia cells: the possible role of protein kinase C in mediation of UVA-induced effects, *Photochem. Photobiol.* 64 (1996) 936–942.
- [56] C. Pourzand, G. Rossier, O. Reelfs, C. Borner, R.M. Tyrrel, Overexpression of Bcl-2 inhibits UVA mediated apoptosis in rat 6 fibroblasts: evidence for the involvement of Bcl-2 as an oxidant, *Cancer Res.* 57 (1997) 1405–1411.
- [57] C.V. Suschek, V. Krischel, D. Bruch-Gerharz, D. Berendji, J. Krutmann, K.-D. Kröncke, V. Kolb-Bachofen, Nitric oxide fully protects against UVA-induced apoptosis in tight correlation with Bcl-2 up-regulation, *J. Biol. Chem.* 274 (1999) 6130–6137.
- [58] V.P. Vallat, P. Gilleaudeau, L. Battat, J. Wolfe, R. Nabeya, N. Heftler, E. Hodak, A.B. Gottlieb, J.G. Krueger, PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy, *J. Exp. Med.* 180 (1994) 283–296.
- [59] T.R. Coven, I.B. Walters, I. Cardinale, J.G. Krueger, PUVA-induced lymphocyte apoptosis: mechanism of action in psoriasis, *Photodermatol. Photoimmunol. Photomed.* 15 (1999) 22–27.